<DOC>
	<DOC>NCT01931761</DOC>
	<brief_summary>To evaluate the absorption, distribution, metabolism and excretion (ADME) of single dose [14C] selumetinib in volunteers</brief_summary>
	<brief_title>Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C] Selumetinib in Volunteers</brief_title>
	<detailed_description />
	<criteria>Provision of signed and dated, written informed consent prior to any study specific procedures. Have a body mass index (BMI) between 18 and 32 kg/m2 inclusive and weigh at least 50 kg and no more than 100 kg, inclusive. Regular bowel movements (ie, on average production of at least 1 stool per day). Current or past history of central serous retinopathy or retinal vein thrombosis, intraocular pressure greater than 21 mmHg or uncontrolled glaucoma. Exposure to radiation levels above background exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years. History or presence of any clinically significant disease or disorder in the opinion of the investigator Any clinically important abnormalities in clinical chemistry, haematology, or urinalysis results, vital signs or ECG at baseline in the opinion of the Investigator.</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Pharmacokinetics, mass balance, AZD6244</keyword>
</DOC>